Movement Alert｜RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound

Market Focus05-21 09:52

On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.

On the news front, the broader biotechnology sector staged a collective rebound, with AKESO surging 7.3%, INNOVENT BIO up 3.4%, SKB BIO up 4.03%, and BEIGENE gaining 3.2%, creating a strong sector linkage effect that lifted sentiment across the board.

From a fundamental perspective, RemeGen's chairman recently stated that telitacicept, having received FDA orphan drug designation, is largely insulated from U.S. drug price reduction policies, and overseas clinical communications with the FDA are progressing smoothly. The company reported Q1 revenue of RMB 656 million, up 24.76% year-over-year, with net profit attributable to shareholders of RMB 328 million, successfully turning losses into profits. Nine institutions have issued buy ratings with an average target price of RMB 150.8, as multiple positive catalysts converge to support price recovery.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115613674?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-21 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115613674","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound","media":"Market Focus","content":"<p><p>On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.</p><p>On the news front, the broader biotechnology sector staged a collective rebound, with AKESO surging 7.3%, INNOVENT BIO up 3.4%, SKB BIO up 4.03%, and BEIGENE gaining 3.2%, creating a strong sector linkage effect that lifted sentiment across the board.</p><p>From a fundamental perspective, RemeGen's chairman recently stated that telitacicept, having received FDA orphan drug designation, is largely insulated from U.S. drug price reduction policies, and overseas clinical communications with the FDA are progressing smoothly. The company reported Q1 revenue of RMB 656 million, up 24.76% year-over-year, with net profit attributable to shareholders of RMB 328 million, successfully turning losses into profits. Nine institutions have issued buy ratings with an average target price of RMB 150.8, as multiple positive catalysts converge to support price recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 3.55% in Regular Trading, Biotech Sector Rally and Strong Q1 Earnings Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-21 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.</p><p>On the news front, the broader biotechnology sector staged a collective rebound, with AKESO surging 7.3%, INNOVENT BIO up 3.4%, SKB BIO up 4.03%, and BEIGENE gaining 3.2%, creating a strong sector linkage effect that lifted sentiment across the board.</p><p>From a fundamental perspective, RemeGen's chairman recently stated that telitacicept, having received FDA orphan drug designation, is largely insulated from U.S. drug price reduction policies, and overseas clinical communications with the FDA are progressing smoothly. The company reported Q1 revenue of RMB 656 million, up 24.76% year-over-year, with net profit attributable to shareholders of RMB 328 million, successfully turning losses into profits. Nine institutions have issued buy ratings with an average target price of RMB 150.8, as multiple positive catalysts converge to support price recovery.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1115613674","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115613674","pubTimestamp":1779328351,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.On the news front, the broader biotechnology sector staged a collective...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"走势提示|RemeGen常规交易涨3.55%生物科技板块反弹Q1盈利强劲带动反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On May 21, RemeGen rose 3.55% in regular trading, trading at HK$88.6/share, with trading volume of approximately HK$112 million.On the news front, the broader biotechnology sector staged a collective rebound, with AKESO surging 7.3%, INNOVENT BIO up 3.4%, SKB BIO up 4.03%, and BEIGENE gaining 3.2%, creating a strong sector linkage effect that lifted sentiment across the board.From a fundamental perspective, RemeGen's chairman recently stated that telitacicept, having received FDA orphan drug designation, is largely insulated from U.S. drug price reduction policies, and overseas clinical communications with the FDA are progressing smoothly. The company reported Q1 revenue of RMB 656 million, up 24.76% year-over-year, with net profit attributable to shareholders of RMB 328 million, successfully turning losses into profits. Nine institutions have issued buy ratings with an average target price of RMB 150.8, as multiple positive catalysts converge to support price recovery.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115613674","isCrawlerRequest":true}